Day: April 16, 2026

Fiocchi, part of the CSG, has introduced a new generation of counter-drone ammunition designed to enable soldiers to effectively engage small unmanned aerial vehicles (UAVs) using standard-issue firearms. The solution was recently unveiled at Enforce Tac 2026 in Nuremberg, one of Europe’s leading exhibitions for internal and homeland security. The new ammunition responds to the rapidly evolving threat posed by small commercial and improvised drones, which have become a defining feature of modern battlefields. While traditional air defence systems are often not suited to counter low-cost, low-altitude UAVs at close range, Fiocchi’s solution provides a simple, immediately available last-line defence capability at the individual soldier level. Designed for standard assault rifles Unlike many existing approaches that rely on shotguns or specialized...

TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications  Berlin, Germany, April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, is pleased to announce a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NOX-A12 + radiotherapy + anti-VEGF “triple therapy” in glioblastoma patients. The article in the scientific peer-reviewed high-impact journal, Nature Communications, describes results of the expansion cohort Arm A in TME Pharma’s Phase 1/2 GLORIA trial. In this arm, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients with residual tumor...

Nokia and Cinia partner to secure Finland’s critical infrastructure with advanced DDoS protectionCinia deploying Nokia advanced Distributed Denial of Service (DDoS) protection solution to safeguard critical networks against evolving cyber threats. Solution’s real-time threat identification aligns with Cinia’s responsibility to maintain resilient infrastructure that underpins Finland’s digital economy.16 April 2026  Espoo, Finland – Nokia today announced it is partnering with Cinia, a leading Finnish provider of critical connectivity and cybersecurity services, to deliver an advanced Distributed Denial of Service (DDoS) protection solution. This collaboration establishes a new managed security service provider (MSSP) model, specifically designed to safeguard critical infrastructure networks against modern, complex...

AS Tallink Grupp will introduce the first quarter 2026 results in an investor webinar. All shareholders and other stakeholders are invited to join the webinar, scheduled to take place on 23 April 2026 at 12:00 (EET). The webinar will be held in English. The financial results will be presented by the Chairman of the Management Board Peep Jalakas and the members of the Management Board Paavo Nõgene and Harri Hanschmidt. We kindly ask participants to provide their questions before the webinar, no later than 11:00 am on 23 April 2026, by e-mail to: investor@tallink.ee. Due to time constraints, preference will be given to questions submitted in writing before the webinar. How to join the webinar?The webinar will be hosted on the Microsoft Teams platform. Please note that to participate, no prior registration is required, and no reminder will...

AS Tallink Grupp will introduce the first quarter 2026 results in an investor webinar. All shareholders and other stakeholders are invited to join the webinar, scheduled to take place on 23 April 2026 at 12:00 (EET). The webinar will be held in English. The financial results will be presented by the Chairman of the Management Board Peep Jalakas and the members of the Management Board Paavo Nõgene and Harri Hanschmidt. We kindly ask participants to provide their questions before the webinar, no later than 11:00 am on 23 April 2026, by e-mail to: investor@tallink.ee. Due to time constraints, preference will be given to questions submitted in writing before the webinar. How to join the webinar?The webinar will be hosted on the Microsoft Teams platform. Please note that to participate, no prior registration is required, and no reminder will...

Kering – Press Release – Capital Markets Day – EN – 16 04 2026PRESS RELEASEApril 16, 2026RECONKERINGTRUE LUXURY. NEXT LUXURY. Kering unveils its strategic vision to reignite desirability, reinforce operational excellence, and lead the next era of luxury. Florence, Italy Kering is holding its Capital Markets Day today and presenting ReconKering, the next chapter of the Group’s transformation. ReconKering is designed to restore clarity, rebuild execution discipline and place the Group back on a long-term leadership trajectory. The strategy reaffirms our foundations in True Luxury – creativity, craftsmanship, cultural relevance and product excellence – and builds the capabilities required to lead the emergence of Next Luxury: new technologies, new client expectations, new markets and new categories. In a challenging...

COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above. The virus-like particle (VLP) single-dose vaccine is the first chikungunya vaccine to receive approval in Switzerland and was approved following review of the regulatory dossier submitted in July 2025, upon the FDA and EMA approvals of the vaccine earlier in 2025. “The Swiss approval marks another important milestone in our endeavors to bring protection against chikungunya to more people and reinforces our commitment to expanding access to our vaccine globally,” said Paul Chaplin, President & CEO of Bavarian Nordic. The approval...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Transaction includes EUR 25.0M investment from EQT Life Sciences Strong additional support from high-quality, long-only and sector specialist investors Cash runway now extends into Q1 2028EINDHOVEN, the Netherlands, April 16, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence...